Cytomegalovirus (CMV) Infection – Comprehensive Medical Guide

Overview

Cytomegalovirus (CMV) is a member of the herpesvirus family, the same group that includes herpes simplex virus and Epstein‑Barr virus. Like other herpesviruses, CMV remains in the body for life after the initial infection and can reactivate, especially when the immune system is weakened.

Who it affects: CMV infects people of all ages and ethnicities. In healthy adults, primary infection often causes no symptoms or a mild, flu‑like illness. However, it can be serious in:

• Newborns (especially those born prematurely or with low birth weight)
• Pregnant women (risk of transmitting the virus to the fetus)
• People with weakened immune systems – such as organ‑transplant recipients, HIV‑positive individuals, and patients receiving chemotherapy or high‑dose steroids

Prevalence: Worldwide, 50‑80 % of adults are seropositive for CMV, meaning they have been exposed at some point in their lives (CDC). In the United States, about 60 % of adults ages 40‑49 have CMV antibodies, and the rate climbs to >90 % in people >80 years old (NIH).

Symptoms

Symptoms vary dramatically based on age, immune status, and whether the infection is primary, reactivated, or congenital.

In Healthy Adults (Primary Infection)

• Fever – usually low‑grade, lasting 1–2 weeks.
• Fatigue – can be profound and persist for weeks.
• Sore throat and swollen lymph nodes, especially behind the ears.
• Muscle aches and joint pain.
• Headache.
• Occasional rash (maculopapular, often on the trunk).

In Immunocompromised Patients

• Pneumonia – non‑productive cough, shortness of breath, and low‑grade fever.
• Colitis – abdominal pain, watery or bloody diarrhea.
• Hepatitis – jaundice, elevated liver enzymes.
• Retinitis – blurry vision, floaters, and possible loss of vision (common in AIDS patients).
• Encephalitis – confusion, seizures, or focal neurological deficits.
• Bone‑marrow suppression – anemia, neutropenia, thrombocytopenia.

Congenital CMV (Newborns)

• Hearing loss (often progressive, may not be apparent at birth).
• Microcephaly or abnormal brain development.
• Jaundice lasting >2 weeks.
• Poor feeding/reflux and failure to thrive.
• Petechial rash (tiny red spots) – “blueberry muffin” rash.
• Seizures or other neurologic signs.
• In severe cases, multisystem disease (lungs, liver, spleen, eyes).

Causes and Risk Factors

CMV spreads through direct contact with infected body fluids. The virus is remarkably stable in the environment and can survive for hours on surfaces.

• Saliva – sharing drinks, utensils, or kissing.
• Urine – especially relevant for diaper‑changing infants.
• Blood and transfusions – although screening has reduced risk in most high‑income countries.
• Sexual contact – semen and vaginal secretions.
• Organ transplantation – donor organ may carry latent virus.
• Prenatal transmission – transplacental infection during maternal primary infection or reactivation.

Key Risk Factors

• Living in crowded or low‑socioeconomic settings (higher early‑life exposure).
• Day‑care attendance for young children (children shed virus in urine for months).
• Having a partner who is CMV‑positive while being pregnant.
• Immunosuppressive therapy (e.g., after organ transplant, chemotherapy).
• Advanced HIV infection (CD4 count <200 cells/µL).

Diagnosis

Because many infections are asymptomatic, laboratory testing is essential.

Serologic Tests

• CMV IgM – indicates recent or primary infection; however, IgM can persist for months.
• CMV IgG – shows past exposure; a rising IgG titer over 2–3 weeks suggests recent infection.

Polymerase Chain Reaction (PCR)

Detects CMV DNA in blood, urine, cerebrospinal fluid (CSF), or tissue. PCR is the preferred method for monitoring viral load in immunocompromised patients and for diagnosing congenital infection (urine or saliva collected within 3 weeks of birth).

Antigenemia Assay (pp65)

Detects CMV protein in white blood cells; useful for rapid screening in transplant centers but less common now due to PCR availability.

Imaging & Specialist Evaluation

• Chest X‑ray/CT – evaluates CMV pneumonia.
• Abdominal imaging – assesses colitis or hepatitis.
• Ophthalmologic exam – essential for suspected CMV retinitis.
• Neuroimaging (MRI/CT) – for encephalitis.

Congenital CMV Testing

1. Collect urine or saliva within the first 3 weeks of life.
2. Perform PCR for CMV DNA.
3. If positive, follow with hearing test (ABR) and neuro‑developmental assessments.

Treatment Options

Treatment decisions depend on the patient’s immune status, disease severity, and organ involvement.

Antiviral Medications

• Ganciclovir (intravenous) – first‑line for severe disease (e.g., CMV pneumonitis, retinitis, colitis). Requires monitoring of blood counts and renal function.
• Valganciclovir (oral pro‑drug) – used for less severe disease and for long‑term suppression; dosage adjusted for kidney function.
• Foscarnet – alternative when ganciclovir‑resistant CMV is identified; nephrotoxic, requires careful electrolyte monitoring.
• Cidofovir – third‑line option; also nephrotoxic.

Adjunctive Measures

• Reduction of immunosuppressive therapy when feasible (e.g., lowering steroid dose) under specialist guidance.
• IV fluids and supportive care for organ dysfunction (e.g., oxygen for pneumonia).
• Transfusion of platelets or red cells if severe cytopenias develop.

Pregnancy and Congenital Infection

• Pregnant women with primary CMV infection may be offered valganciclovir in a clinical‑trial setting; routine treatment is not universally recommended due to limited safety data.
• Infants with symptomatic congenital CMV are treated with 6 weeks of oral valganciclovir (or IV ganciclovir if severe) to improve hearing and neurodevelopmental outcomes (CDC).

Lifestyle & Supportive Strategies

• Good hand‑hygiene and avoiding sharing utensils during active infection.
• Regular ophthalmology visits for patients at risk of retinitis.
• Vaccination against other infections (influenza, pneumococcal) to reduce overall immune burden.

Living with Cytomegalovirus (CMV) Infection

Even after treatment, CMV remains in the body. Managing daily life focuses on monitoring, preventing reactivation, and maintaining overall health.

Monitoring

• For transplant recipients, follow viral load (PCR) at least weekly during the first 3 months post‑transplant, then monthly as directed.
• Report new visual changes, persistent fevers, or gastrointestinal symptoms promptly.

Nutrition & General Health

• Eat a balanced diet rich in fruits, vegetables, lean protein, and whole grains to support immune function.
• Stay hydrated; dehydration can worsen kidney side‑effects of antivirals.
• Limit alcohol and avoid tobacco – both can impair immune response.

Medication Adherence

• Take antivirals exactly as prescribed; missing doses can lead to resistance.
• Use pill organizers or smartphone reminders.

Psychosocial Support

• Join support groups for transplant or HIV patients; peer sharing eases anxiety.
• Consider counseling if chronic illness leads to depression or anxiety.

Prevention

Because CMV is so common, complete avoidance isn’t realistic, but risk can be markedly reduced.

• Hand hygiene: Wash hands with soap and water for at least 20 seconds after diaper changes, using the bathroom, or handling saliva‑containing objects.
• Safe food handling: Cook meat thoroughly; avoid unpasteurized dairy.
• Blood product safety: In the U.S., blood is screened for CMV; request CMV‑negative or leukoreduced blood if you are high‑risk (e.g., pregnant, transplant).
• Sexual health: Use condoms, especially if a partner’s CMV status is unknown.
• Pregnancy-specific: Women planning pregnancy should have CMV serology; if seronegative, avoid close contact with toddlers’ urine/saliva and practice strict hygiene.
• Vaccination research: A CMV vaccine is under development (Phase III trials as of 2023) but not yet commercially available (WHO).

Complications

If untreated or inadequately managed, CMV can cause serious, sometimes irreversible problems.

• Vision loss from CMV retinitis, especially in AIDS patients (up to 30 % without treatment).
• Permanent hearing loss in congenitally infected infants – affects 10‑15 % of symptomatic newborns.
• Chronic organ dysfunction – interstitial lung disease, ulcerative colitis, or hepatic fibrosis.
• Neurologic deficits – seizures, cognitive impairment, or motor weakness after encephalitis.
• Graft loss in transplant recipients due to CMV‑induced inflammation.
• Increased mortality – CMV disease contributes to 10‑20 % of deaths in solid‑organ transplant recipients (Cleveland Clinic).

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, NIH, WHO, Cleveland Clinic, peer‑reviewed journals (e.g., Clinical Infectious Diseases, JAMA Pediatrics).